Viking Therapeutics reported an 8.2% weight loss with VK2735, but a sell-off followed. Read why VKTX stock's long-term prospects remain positive.

Here are the key points about Viking Therapeutics' oral obesity drug VK2735: Early-Stage Trial Results: All doses of VK2735 demonstrate at least 10% weight loss compared with 4% for placebo. The trial is conducted in 28 days. And those with the highest dose of 100 mg lost an average of 8.2% of body weight.